Clinical Cancer Research (journal)

August 12, 2021

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

By Tom Wilemon
April 23, 2020

Study explores melanoma drug’s effectiveness

A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

By Tom Wilemon
February 27, 2020

Breast cancer study may help predict treatment response

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

By Bill Snyder
November 20, 2019

Study finds breast cancer recurrence score has different implications for men

A study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence. However, a new study finds this conclusion may not directly apply to male patients with the same type of breast cancer

By Tom Wilemon
From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

By Tom Wilemon
February 20, 2017

Improving therapies for GI tumors

A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.

By Leigh MacMillan
May 3, 2016

Drug combos for glioblastoma

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
By Leigh MacMillan
November 13, 2015

Five candidates sought for Runyon Cancer Clinical Investigator Award

Vanderbilt University may nominate five candidates for the 2016 Damon Runyon Cancer Research Foundation Clinical Investigator Award.
By VUMC News and Communications
May 8, 2014

PET probe detects dying tumor cells

A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.
By Leigh MacMillan
March 20, 2013

New drugs a good BET for brain cancer

A novel class of drugs that target “BET” proteins may have broad utility for treating genetically diverse brain tumors.
By Leigh MacMillan
April 26, 2012

New drug mutes more melanomas

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.
By VUMC News and Communications
April 6, 2012

Factor sensitizes cancer to radiation

Measuring levels of an enzyme in head and neck tumors may indicate how the tumor will respond to radiation therapy.
By VUMC News and Communications